TITLE

Pfizer King of M&As

PUB. DATE
November 2010
SOURCE
Pharmaceutical Representative;Nov2010, Vol. 40 Issue 11, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the merger agreement between Pfizer Inc. and King Pharmaceuticals Inc. in the U.S.
ACCESSION #
55433846

 

Related Articles

  • Pfizer to Acquire King Pharmaceuticals, Inc.  // Chicago Citizen - South Suburban Edition;10/20/2010, Vol. 29 Issue 50, p4 

    The article offers information regarding the merger agreement between Pfizer Inc. and King Pharmaceuticals Inc.

  • King Buy to Bolster Pfizer In Pain Medication Arena.  // Chain Drug Review;10/25/2010, Vol. 32 Issue 18, p69 

    The article reports on the acquisition of King Pharmaceuticals Inc. by Pfizer Inc. in operating tamper-resistant medicines in New York in 2010.

  • Pfizer to Acquire King Pharmaceuticals, Inc.  // Chicago Citizen;10/20/2010, Vol. 45 Issue 30, p4 

    The article reports on the definitive merger agreement entered by Pfizer Inc. to acquire King Pharmaceuticals Inc., a diversed specialty drugs research and clinical company.

  • Pfizer makes $3.6B deal for King Pharmaceuticals. Kaitwasser, Jared // njbiz;10/18/2010, Vol. 23 Issue 42, p10 

    The article reports that pharmaceutical company Pfizer Inc. is set to purchase Tennessee-based King Pharmaceuticals Inc., a company that develops pain relief products and technologies.

  • TOP STORIES.  // MondayMorning;10/18/2010, Vol. 18 Issue 38, p1 

    The article offers news briefs related pharmaceutical industry of the U.S. Pfizer Inc. acquires King Pharmaceuticals Inc. for 3.6 billion dollars, the deal is expected to close at the first quarter of 2011. The U.S. Food and Drug Administration (FDA) decides to revoke the approval on a patch for...

  • Hostile Takeover Bids Are Increasing As Companies Rebuff Friendly Offers. Platt, Gordon // Global Finance;Nov2010, Vol. 24 Issue 10, p59 

    The article reports on the increase in hostile takeover bids worldwide. Thomson Reuters unveils that the value of merger and acquisition (M&A) activity in the first three quarters of 2010 reached 1.75 trillion U.S. dollars. Companies involved in the M&A activity include Pfizer Inc., King...

  • Pfizer Inc. SWOT Analysis.  // Pfizer, Inc. - SWOT Analysis;Oct2012, p1 

    A business analysis of Pfizer Inc., the largest biopharmaceutical company in the world, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include its acquisition of King Pharmaceuticals. Weaknesses include its heavy reliance...

  • King gives Pfizer sales edge in the pain game. Comer, Ben // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p13 

    The article reports on the acquisition of King Pharmaceuticals Inc. by Pfizer Inc. in the U.S. It indicates that the acquisition aims to expand Pfizer's portfolio in the producing pain medications by adding Embeda, Avinza and the Flector Patch to its Lyrica and Celebrex product ranges. Moreover,...

  • Will King Give Pfizer a Royal Flush in the Pain Market? Young, Donna // BioWorld Today;10/13/2010, Vol. 21 Issue 198, p1 

    The article reports that Pfizer Inc. has proposed to acquire King Pharmaceuticals Inc. for 3.6 billion U.S. dollars. News of the proposed acquisition have increase share prices of King and Acura Pharmaceuticals Inc. If the acquisition pushes through, Pfizer will gain partnerships with other...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics